Business Context and Reporting Period
This Form 8-K filing by Tempest Therapeutics, Inc. (TPST) reports a change in executive leadership. The report date is August 18, 2026, covering events effective September 1, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure: Mr. Justin Trojanowski resigned as Principal Financial Officer and Principal Accounting Officer, effective September 1, 2026.
- Appointment: Mr. Nicholas Rossettos was appointed as Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, effective September 1, 2026.
Outlook, Risks, and Management Commentary
Mr. Rossettos brings over 30 years of experience in biopharmaceutical and life sciences organizations, including recent roles as a financial advisor to TransCode Therapeutics, Inc. and Interim CFO of Sernova Corp. He holds an MBA in Accounting and is a certified public accountant. The filing states there are no family relationships between Mr. Rossettos and current directors or officers, and no undisclosed arrangements regarding his appointment.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (September 1, 2026).
- Review Mr. Rossettos' background for potential conflicts of interest with competitors.
- Monitor subsequent filings for any interim financial reporting gaps during the transition.
- Verify if the departure of Mr. Trojanowski was related to any undisclosed financial irregularities.